Abstract
Life expectancy has impressively increased over the past century and the US population over 65 years is rapidly growing, especially those over 80 years. In fact, persons older than 80 years have increased by more than 250% between the years 1960 and 2000, and it is expected that the population aged >75 years will triple by the year 2030. With the increase of the geriatric population, there is a need for the development and validation of treatment strategies for NHL for these patients. Therapy in elderly patients needs special attention because older patients usually suffered of several co-morbidities and their management represents a challenge for physicians. In fact, older patients treated for lymphoma may not tolerate the high-dose therapies used in younger patients and have increased risk of therapy-related toxicity as a result of age-related physiological changes and frequent co-morbidities. The widespread use of a comprehensive geriatric assessment tool might overcome the difficulty to run prospective clinical trial in elderly patients with lymphoma.
Keywords: Elderly patients, lymphoma, comprehensive geriatric assessment, therapy related toxicity.
Anti-Cancer Agents in Medicinal Chemistry
Title:Management Of Elderly Patients With Diffuse Large B-Cell Lymphomas
Volume: 13 Issue: 9
Author(s): Rosanna Ciancia, Umberto Tirelli, Josep-Maria Ribera and Michele Spina
Affiliation:
Keywords: Elderly patients, lymphoma, comprehensive geriatric assessment, therapy related toxicity.
Abstract: Life expectancy has impressively increased over the past century and the US population over 65 years is rapidly growing, especially those over 80 years. In fact, persons older than 80 years have increased by more than 250% between the years 1960 and 2000, and it is expected that the population aged >75 years will triple by the year 2030. With the increase of the geriatric population, there is a need for the development and validation of treatment strategies for NHL for these patients. Therapy in elderly patients needs special attention because older patients usually suffered of several co-morbidities and their management represents a challenge for physicians. In fact, older patients treated for lymphoma may not tolerate the high-dose therapies used in younger patients and have increased risk of therapy-related toxicity as a result of age-related physiological changes and frequent co-morbidities. The widespread use of a comprehensive geriatric assessment tool might overcome the difficulty to run prospective clinical trial in elderly patients with lymphoma.
Export Options
About this article
Cite this article as:
Ciancia Rosanna, Tirelli Umberto, Ribera Josep-Maria and Spina Michele, Management Of Elderly Patients With Diffuse Large B-Cell Lymphomas, Anti-Cancer Agents in Medicinal Chemistry 2013; 13 (9) . https://dx.doi.org/10.2174/18715206113136660363
DOI https://dx.doi.org/10.2174/18715206113136660363 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Stem Cells in Brain Tumorigenesis and their Impact on Therapy
Current Stem Cell Research & Therapy Transient Abnormal Myelopoiesis in Down’s Syndrome - A Diagnostic Dilemma
Applied Clinical Research, Clinical Trials and Regulatory Affairs Metabotropic Glutamate Receptor 5 in Down's Syndrome Hippocampus During Development: Increased Expression in Astrocytes
Current Alzheimer Research Biochemical Markers of Renal Function
Current Medicinal Chemistry Pleiotropic Effects of Tocotrienols and Quercetin on Cellular Senescence: Introducing the Perspective of Senolytic Effects of Phytochemicals
Current Drug Targets Eph/Ephrin Membrane Proteins: A Mammalian Expression Vector pTIg- BOS-Fc Allowing Rapid Protein Purification
Protein & Peptide Letters Pharmacology and Therapeutic Applications of A3 Receptor Subtype
Current Topics in Medicinal Chemistry Bioactivities of Iridoids
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Neurokinin Receptors as Potential Targets in Breast Cancer Treatment
Current Drug Discovery Technologies The Role of STAT3 Signaling in Mediating Tumor Resistance to Cancer Therapy
Current Drug Targets Linezolid Activity Against Disseminated Listeria monocytogenes Meningitis and Central Nervous System Abscesses: Focus on Early Drug Myelotoxicity
Current Drug Safety New Derivatives of GnRH as Potential Anticancer Therapeutic Agents
Current Medicinal Chemistry The Enzymology of Cytosolic Pyrimidine 5’-Nucleotidases: Functional Analysis and Physiopathological Implications.
Current Medicinal Chemistry Enhancing the Cytotoxic Activity of Novel Targeted Therapies – Is There a Role for a Combinatorial Approach?
Current Clinical Pharmacology Cellular Changes, Molecular Pathways and the Immune System Following Photodynamic Treatment
Current Medicinal Chemistry Natural Medicine:The Genus Angelica
Current Medicinal Chemistry Synthesis and Photobiological Properties of Bromo- and Alkoxymethyl Furocoumarins
Letters in Drug Design & Discovery The Biological Effects of Diagnostic Cardiac Imaging
Current Pharmaceutical Design Vitamin D3 and Vitamin D3 Analogues as an Adjunct to Cancer Chemotherapy and Radiotherapy
Current Medicinal Chemistry - Anti-Cancer Agents Membrane Transporters as Determinants of the Pharmacology of Platinum Anticancer Drugs
Current Cancer Drug Targets